| Correction to Lancet Respir Med 2021; published online Jan 8. https://doi.org/10.1016/S2213-2600(20)30552-X | Lancet Respiratory Medicine | 666 days | save |  |  |  |
| Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial | Lancet Respiratory Medicine | 666 days | save | | | |
| New and old treatments for malignant mesothelioma: not just immunotherapy | Lancet Respiratory Medicine | 666 days | save | | | |
| Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial | Lancet Respiratory Medicine | 666 days | save | | | |
| Correction to Lancet Respir Med 2020; published online Dec 22. https://doi.org/10.1016/S2213-2600(20)30414-8 | Lancet Respiratory Medicine | 668 days | save | | | |
| Use of point-of-care testing for respiratory viruses in hospital | Lancet Respiratory Medicine | 671 days | save | | | |
| Touch, and the absence of it | Lancet Respiratory Medicine | 671 days | save | | | |
| Untouched | Lancet Respiratory Medicine | 671 days | save | | | |
| Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia | Lancet Respiratory Medicine | 671 days | save | | | |
| Face masks in the post-COVID-19 era: a silver lining for the damaged tuberculosis public health response? | Lancet Respiratory Medicine | 671 days | save | | | |
| Each person is a world in COVID-19 | Lancet Respiratory Medicine | 671 days | save | | | |
| Visionary insight | Lancet Respiratory Medicine | 671 days | save | | | |
| Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial | Lancet Respiratory Medicine | 671 days | save | | | |
| The right place for IL-1 inhibition in COVID-19 | Lancet Respiratory Medicine | 671 days | save | | | |
| Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial | Lancet Respiratory Medicine | 671 days | save | | | |
| α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action | Lancet Respiratory Medicine | 672 days | save | | | |
| Realising the potential of SARS-CoV-2 vaccines—a long shot? | Lancet Respiratory Medicine | 674 days | save | | | |
| My COVID-19 dream: training enough health workers | Lancet Respiratory Medicine | 674 days | save | | | |
| An issue of trust—vaccinating Black patients against COVID-19 | Lancet Respiratory Medicine | 674 days | save | | | |
| Trial participants' rights after authorisation of COVID-19 vaccines | Lancet Respiratory Medicine | 675 days | save | | | |
| Assessing the importance of interleukin-6 in COVID-19 – Authors' reply | Lancet Respiratory Medicine | 677 days | save | | | |
| Assessing the importance of interleukin-6 in COVID-19 | Lancet Respiratory Medicine | 677 days | save | | | |
| Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study | Lancet Respiratory Medicine | 677 days | save | | | |
| Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data | Lancet Respiratory Medicine | 677 days | save | | | |
| Misdiagnosis of sarcoidosis | Lancet Respiratory Medicine | 677 days | save | | | |
| Pandemic thoughts from a British junior doctor in Melbourne | Lancet Respiratory Medicine | 677 days | save | | | |
| Correction to Lancet Respir Med 2020; published online October 20. https://doi.org/10.1016/S2213-2600(20)30391-X | Lancet Respiratory Medicine | 677 days | save | | | |
| 180 degree shift | Lancet Respiratory Medicine | 677 days | save | | | |
| COVID-19: the lessons learned amongst the losses | Lancet Respiratory Medicine | 677 days | save | | | |
| NICE guideline on long COVID | Lancet Respiratory Medicine | 680 days | save | | | |
| Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks | Lancet Respiratory Medicine | 682 days | save | | | |
| Improving family access to dying patients during the COVID-19 pandemic | Lancet Respiratory Medicine | 682 days | save | | | |
| Are women with asthma at increased risk for severe COVID-19? | Lancet Respiratory Medicine | 682 days | save | | | |
| Improving clinical management of COVID-19: the role of prediction models | Lancet Respiratory Medicine | 682 days | save | | | |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study | Lancet Respiratory Medicine | 682 days | save | | | |
| Implications of COVID-19 sequelae for health-care personnel | Lancet Respiratory Medicine | 682 days | save | | | |
| Sedation in mechanically ventilated patients with COVID-19 | Lancet Respiratory Medicine | 685 days | save | | | |
| Consensus on the referral and admission of patients with severe respiratory failure to the NHS ECMO service | Lancet Respiratory Medicine | 685 days | save | | | |
| Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study | Lancet Respiratory Medicine | 685 days | save | | | |
| A new year, but familiar challenges from COVID-19 in the USA | Lancet Respiratory Medicine | 685 days | save | | | |
| Renin-angiotensin system inhibitors in hospitalised patients with COVID-19 | Lancet Respiratory Medicine | 686 days | save | | | |
| Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial | Lancet Respiratory Medicine | 686 days | save | | | |
| New variant of SARS-CoV-2 in UK causes surge of COVID-19 | Lancet Respiratory Medicine | 688 days | save | | | |
| Correction to Lancet Respir Med 2021; 9: 69–84 | Lancet Respiratory Medicine | 690 days | save | | | |
| Correction to Lancet Respir Med 2021; 9: 57–68 | Lancet Respiratory Medicine | 690 days | save | | | |
| Overdiagnosis in lung cancer screening | Lancet Respiratory Medicine | 690 days | save | | | |
| Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial | Lancet Respiratory Medicine | 702 days | save | | | |
| Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial | Lancet Respiratory Medicine | 706 days | save | | | |
| Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study | Lancet Respiratory Medicine | 707 days | save | | | |
| Personalised medicine for asthma in a post-pandemic world | Lancet Respiratory Medicine | 707 days | save | | | |
| | 
report | next » |
| |
